摘要
嘌呤能系统由嘌呤和嘧啶递质、调节核苷酸和核苷相互转化的酶、控制它们的受体的膜转运体组成。无细胞浓度,以及许多受体亚型,负责他们的细胞反应。这个系统的组成部分在所有的组织和器官中都有广泛的定位。R参与了几种生理条件已被清楚地证明。此外,在像tiss这样的病理条件下,细胞外嘌呤和嘧啶的浓度增加了几倍。UE损伤,缺血和炎症,这表明这一信号系统可能有助于疾病的结果,并可能,它的初步解决。这个系统的复杂性由于不同的受体亚型所扮演的角色往往相反,实际上参与某一特定病理过程的介质和受体的明确识别受到了严重的损害。n然而,这些知识对于可能利用这些分子实体作为开发新的药理方法的目标是非常重要的。在这篇综述中,我们的目标是高效率。了解目前已知的嘌呤能系统在各种疼痛状态和炎症过程中的作用。虽然有些混淆可能会从相互矛盾的结果中产生,但文献数据清楚地表明,靶向特定的嘌呤能受体可能是治疗各种疼痛和炎症状态的一种创新方法,而新的嘌呤类药物现在非常接近r。每个市场都有这些迹象。
关键词: P1受体、P2X受体、P2Y受体、腺苷、ATP、UTP、核糖核苷酶、膜转运蛋白。
Current Medicinal Chemistry
Title:Tackling Chronic Pain and Inflammation through the Purinergic System
Volume: 25 Issue: 32
关键词: P1受体、P2X受体、P2Y受体、腺苷、ATP、UTP、核糖核苷酶、膜转运蛋白。
摘要: The purinergic system is composed of purine and pyrimidine transmitters, the enzymes that modulate the interconversion of nucleotides and nucleosides, the membrane transporters that control their extracellular concentrations, and the many receptor subtypes that are responsible for their cellular responses. The components of this system are ubiquitously localized in all tissues and organs, and their involvement in several physiological conditions has been clearly demonstrated. Moreover, extracellular purine and pyrimidine concentrations rise several folds under pathological conditions like tissue damage, ischemia, and inflammation, which suggest that this signaling system might contribute both to disease outcome and, possibly, to its tentative resolution. The complexity of this system has greatly impaired the clear identification of the mediators and receptors that are actually involved in a given pathology, also due to the often opposite roles played by the various receptor subtypes. Nevertheless, this knowledge is fundamental for the possible exploitation of these molecular entities as targets for the development of new pharmacological approaches. In this review, we aim at highlighting what is currently known on the role of the purinergic system in various pain conditions and during inflammatory processes. Although some confusion may arise from conflicting results, literature data clearly show that targeting specific purinergic receptors may represent an innovative approach to various pain and inflammatory conditions, and that new purine-based drugs are now very close to reach the market with these indications.
Export Options
About this article
Cite this article as:
Tackling Chronic Pain and Inflammation through the Purinergic System, Current Medicinal Chemistry 2018; 25 (32) . https://dx.doi.org/10.2174/0929867324666170710110630
DOI https://dx.doi.org/10.2174/0929867324666170710110630 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Dental Pulp from Human Exfoliated Deciduous Teeth-derived Stromal Cells Demonstrated Neuronal Potential: In Vivo and In Vitro Studies
Current Stem Cell Research & Therapy Inflammatory Mechanisms of Injury and Recovery after Intracerebral Hemorrhage
Current Immunology Reviews (Discontinued) Calorie Restriction and Dietary Restriction Mimetics: A Strategy for Improving Healthy Aging and Longevity
Current Pharmaceutical Design The Role of Platelets and their Microparticles in Rehabilitation of Ischemic Brain Tissue
CNS & Neurological Disorders - Drug Targets Glioma: Tryptophan Catabolite and Melatoninergic Pathways Link microRNA, 14-3- 3, Chromosome 4q35, Epigenetic Processes and other Glioma Biochemical Changes
Current Pharmaceutical Design Indoleamine 2,3-Dioxygenase in Materno-Fetal Interaction
Current Drug Metabolism Seeing Genes at Work in the Living Brain with Non-Invasive Molecular Imaging
Current Gene Therapy Therapeutical Approaches of Vasoactive Intestinal Peptide as a Pleiotropic Immunomodulator
Current Pharmaceutical Design Edelfosine in Membrane Environment - the Langmuir Monolayer Studies
Anti-Cancer Agents in Medicinal Chemistry Mechanisms of Immune Modulation by Mesenchymal Stromal Cells and Clinical Translation
Current Molecular Medicine Modulation of Apoptosis in Acute Ischemic Stroke as Treatment Challenges
Current Immunology Reviews (Discontinued) The Role of Heme Oxygenase-1 in T Cell-Mediated Immunity: The All Encompassing Enzyme
Current Pharmaceutical Design The Interplay between the Gut Immune System and Microbiota in Health and Disease: Nutraceutical Intervention for Restoring Intestinal Homeostasis
Current Pharmaceutical Design Potential Use of Nanomedicine for Drug Delivery Across the Blood-Brain Barrier in Healthy and Diseased Brain
CNS & Neurological Disorders - Drug Targets Human Rabies Encephalitis Prevention and Treatment: Progress Since Pasteurs Discovery
Infectious Disorders - Drug Targets Acute Graft-Versus-Host Disease-Challenge for a Broader Application of Allogeneic Hematopoietic Cell Transplantation
Current Stem Cell Research & Therapy Preparation and Characterization of MKT-077 Nanoparticles for Treatment of Alzheimer’s Disease and Other Tauopathies
Pharmaceutical Nanotechnology Microglial dependent protective effects of neuroactive steroids
CNS & Neurological Disorders - Drug Targets Anti-Arthritic Effects of Immunomodulatory Peptide Injected in Joints
Current Drug Delivery The Identification and Optimization of Orally Efficacious, Small Molecule VLA-4 Antagonists
Current Topics in Medicinal Chemistry